載入...
Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia
Dasatinib, a second-generation tyrosine kinase inhibitor, is used for treating patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who are resistant or intolerant to imatinib. The common adverse effects associated to its use include myelosuppression, nausea, diarrhea,...
Na minha lista:
| 發表在: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4423504/ https://ncbi.nlm.nih.gov/pubmed/25960668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S83961 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|